Stay updated with breaking news from Creative Biolabs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "Fluorescent in Situ Hybridization (FISH) Probe Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026"...
/PRNewswire/ -- The humanized mouse model market size is expected to increase by USD 119.20 million from 2021 to 2025. However, the market's growth momentum is...
Infusion toxicology studies are conducted in toxicologically relevant species to assess the preclinical safety of drugs intended for intravenous administration in human subjects. Infusion toxicology studies help to determine the effective and safe concentration of drug in systemic circulation, which can produce the...
According to the report, the global exosome technologies market was valued over US$ 31 Mn in 2020 and is projected to expand at a CAGR of ~24% from 2021 to 2031.
COLLEGE STATION, TX / ACCESSWIRE / July 20, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (“Enzolytics” and the ‘Company’) announces the signing of a Letter of Intent (LOI) with Creative Biolabs (“Creative”) (https://www.creative-biolabs.com) to complete the joint production and commercialization of HTLV-1 monoclonal antibodies by combining the technologies of the companies. There are no effective vaccines against HTLV-1 and no antiviral drugs available for treating infections caused by the virus. The technologies of Enzolytics and Creative will be combined to achieve the objective of ...